Skip to content

Study · Randomized controlled trial · n = 204 · 2016

4 results

Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.

Buil-Bruna N, Dehez M, Manon A, Nguyen TX, Trocóniz IF

The AAPS journal23 Feb 2016Cited by 21 (Europe PMC)

PMID26908127 (opens in a new tab)PMCIDPMC5256603 (opens in a new tab)DOI10.1208/s12248-016-9884-3 (opens in a new tab)PepBankPUB-26908127
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In GEP-NET patients, disease progression occurred in 27 lanreotide recipients versus 49 placebo recipients.

    In plain wordsDisease progression occurred in fewer lanreotide recipients than placebo recipients.

    Peptide
    Lanreotide
    Outcome
    DecreaseDisease progression events
    Study

    n = 204

    Comparator
    Placebo
    Outcome group
    Tumor growth · Cancer
    Studied dose
    120 mg every 4 weeks · deep subcutaneous · 96 weeksAs given in this study (human).

    Measurements

    Patients with disease progression
    27 patients
    lanreotide 120 mg
    Patients with disease progression
    49 patients
    placebo
    Patients with disease progression
    76 patients
    all patients

    Source sentences

    Summary
    Data for 810 LAN and 1298 CgA serum samples (n = 632 placebo and n = 666 LAN) were used to develop a parametric time-to-event model to relate CgA levels and PFS (76 patients experienced disease progression: n = 49 placebo and n = 27 LAN).
    1 context sentence
    Summary · context
    In CLARINET, a phase III, randomized, double-blind, placebo-controlled study, 204 patients received deep subcutaneous injections of LAN 120 mg (n = 101) or placebo (n = 103) every 4 weeks for 96 weeks.
  2. 02HumanNon-randomized trialPharmacokinetics

    In GEP-NET patients, measured lanreotide serum profiles followed a one-compartment disposition model.

    In plain wordsMeasured lanreotide blood profiles in patients followed a one-compartment model.

    Peptide
    Lanreotide
    Outcome
    Not applicableLanreotide disposition model
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    120 mg every 4 weeks · deep subcutaneous · 96 weeksAs given in this study (human).

    Source sentences

    Summary
    LAN serum profiles were described by a one-compartment disposition model.
    2 context sentences
    Summary · context
    In CLARINET, a phase III, randomized, double-blind, placebo-controlled study, 204 patients received deep subcutaneous injections of LAN 120 mg (n = 101) or placebo (n = 103) every 4 weeks for 96 weeks.
    Summary · context
    Data for 810 LAN and 1298 CgA serum samples (n = 632 placebo and n = 666 LAN) were used to develop a parametric time-to-event model to relate CgA levels and PFS (76 patients experienced disease progression: n = 49 placebo and n = 27 LAN).
  3. 03HumanNon-randomized trialPharmacokinetics

    In GEP-NET patients, lanreotide absorption had two parallel pathways with first- and zero-order kinetics.

    In plain wordsIn patients, lanreotide absorption followed two parallel pathways.

    Peptide
    Lanreotide
    Outcome
    Not applicableLanreotide absorption kinetics
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    120 mg every 4 weeks · deep subcutaneous · 96 weeksAs given in this study (human).

    Source sentences

    Summary
    Absorption was characterized by two parallel pathways following first- and zero-order kinetics.
    2 context sentences
    Summary · context
    In CLARINET, a phase III, randomized, double-blind, placebo-controlled study, 204 patients received deep subcutaneous injections of LAN 120 mg (n = 101) or placebo (n = 103) every 4 weeks for 96 weeks.
    Summary · context
    Data for 810 LAN and 1298 CgA serum samples (n = 632 placebo and n = 666 LAN) were used to develop a parametric time-to-event model to relate CgA levels and PFS (76 patients experienced disease progression: n = 49 placebo and n = 27 LAN).
  4. 04HumanNon-randomized trialMechanism

    In GEP-NET patients, lanreotide-induced chromogranin A decreases followed an inhibitory E MAX model.

    In plain wordsIn patients, measured chromogranin A decreases during lanreotide treatment followed an inhibitory model.

    Peptide
    Lanreotide
    Outcome
    DecreaseChromogranin A decrease
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer
    Studied dose
    120 mg every 4 weeks · deep subcutaneous · 96 weeksAs given in this study (human).

    Source sentences

    Summary
    The LAN-induced decrease in CgA levels was described by an inhibitory E MAX model.
    2 context sentences
    Summary · context
    In CLARINET, a phase III, randomized, double-blind, placebo-controlled study, 204 patients received deep subcutaneous injections of LAN 120 mg (n = 101) or placebo (n = 103) every 4 weeks for 96 weeks.
    Summary · context
    Data for 810 LAN and 1298 CgA serum samples (n = 632 placebo and n = 666 LAN) were used to develop a parametric time-to-event model to relate CgA levels and PFS (76 patients experienced disease progression: n = 49 placebo and n = 27 LAN).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.